Skip to main content
. 2021 Nov 27;9(12):1402. doi: 10.3390/vaccines9121402

Figure 4.

Figure 4

Level of antibodies in IgA and IgG classes one month after the first dose of Pfizer-BioNTech anti-SARS-CoV-2 vaccine expressed in ratio (semi-quantitative Euroimmun test) in the non-previously SARS-CoV-2 infected participants control group (n = 33) and in convalescents (n = 17).